[Federal Register Volume 66, Number 197 (Thursday, October 11, 2001)]
[Notices]
[Pages 51969-51970]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-25447]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated September 26, 2000, and published in the Federal 
Register on October 13, 2000, (65 FR 60978), Guilford Pharmaceuticals, 
Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of cocaine (9041), a basic class 
of controlled substance listed in Schedule II.
    The firm plans to manufacture methyl-3-beta-(4-
trimethylstannylphenyl)-tropane-2-carboxylate as a final intermediate 
for the production of dopascan injection.
    No comments or objections have been received. DEA has considered 
the factors in Title 21, United States Code, section 823(a) and 
determined that the registration of Guilford Pharmaceuticals to 
manufacture the listed controlled substance is consistent with the 
public interest at this time. DEA has investigated the firm on a 
regular basis to ensure that the company's continued registration is 
consistent with the public interest. These investigations have included 
inspection and testing of the company's physical security systems, 
audits of the company's records, verification of the company's 
compliance with state and local laws, and a review of the company's 
background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 
0.100 and 0.104, the Deputy Assistant Administrator, Office of 
Diversion Control, hereby orders that the application submitted by the 
above firm

[[Page 51970]]

for registration as a bulk manufacturer of the basic class of 
controlled substance listed above is granted.

    Dated: September 25, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 01-25447 Filed 10-10-01; 8:45 am]
BILLING CODE 4410-09-M